French company seeks partners in cardiology, medical imaging or artificial intelligence to distribute Quantified Imaging Resource (QIR-MR) medical device

- SCHEDA
- APPROFONDIMENTI

Identificativo proposta:BOFR20211015001 **RICHIEDI MAGGIORI INFORMAZIONI**

A French company that specialises in medical imaging has designed and developed a post processing software for cardiac MRI (Medical Resonance Imaging) based on artificial intelligence. The company is willing to expand its presence via distributors worldwide. Ideally, the partners sought are acting in cardiology, medical imaging or artificial intelligence and have a strong position in their country.

The medical device offered by the French company is a post processing software for cardiac MRI (Medical Resonance Imaging) based on artificial intelligence (AI) and deep learning algorithms. The algorithm is the first to offer an AI-based anatomical guarantee, which implies that the contour is correctly positioned on the heart and therefore reduces the risk of misdetection. In addition, the software incorporates the first false positive detection algorithm for myocardial infarction. This clinical expertise allows the doctor to make a more relevant diagnosis and save time. It is also designed to be easy to use, flexible to be used on an entry-level computer and with all MRI and visual manufacturers. Available in 6 languages, it adapts to the international context in which the sector evolves. The main objective of this innovative medical device enables to detect the different areas of the heart in order to quantify the clinical parameters and to help with cardiac diagnosis. The system allows doctor's working time to be reduced by a factor of 10 and it solves a major problem encountered by practitioners to correct the contours which are drawn automatically and inaccurately. This diagnostic software has 4 modules integrating the main sequences necessary for the physician to perform his diagnosis such as in Cine (Cardiac function and Strain), Late enhancement, First Pass, Mapping (T1, T2, T3), Aortic Flow and Compliance. There different modules allow to highlight pathologies such as myocardial diseases, strokes and tumors. The device is CE marked according to the European classification system and FDA clearance is under progress. The company is ISO 13485 certified. The company is now seeking partners to expand its presence worldwide and distribute the software in Shengen space countries and countries such UK, USA, Africa, China, Taiwan, Japan, Singapore, Korea, India, Vietnam, Thailand.

Riferimento Esterno: BOFR20211015001
Tipo: Business Offer
Paese: France

Presentazione: 02/11/2021
Ultimo aggiornamento: 16/11/2021
Scadenza: 17/11/2022